Landscape Capital Management L.L.C. Acquires New Stake in Elanco Animal Health Incorporated $ELAN

Landscape Capital Management L.L.C. acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 114,471 shares of the company’s stock, valued at approximately $2,817,000.

A number of other large investors also recently bought and sold shares of the company. NewEdge Advisors LLC increased its stake in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Elanco Animal Health during the second quarter worth about $38,000. Root Financial Partners LLC lifted its position in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health in the fourth quarter valued at about $41,000. Finally, Torren Management LLC purchased a new stake in Elanco Animal Health in the 4th quarter valued at approximately $46,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 2.1%

Shares of NYSE ELAN opened at $24.05 on Friday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98. The firm has a 50-day moving average price of $24.56 and a 200 day moving average price of $24.01. The stock has a market capitalization of $12.02 billion, a price-to-earnings ratio of -58.66, a price-to-earnings-growth ratio of 1.41 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the previous year, the firm earned $0.26 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. UBS Group boosted their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. KeyCorp lifted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. upped their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Insider Activity at Elanco Animal Health

In other news, Director Paul Herendeen purchased 10,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the acquisition, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. The trade was a 9.83% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $23.08 per share, with a total value of $96,936.00. Following the completion of the purchase, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.